Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXN9SK
|
||||
| Drug Name |
4-(3-(piperidin-1-yl)propyl)-6-(3-(trifluoromethyl)phenyl)pyrimidine-2-carbonitrile
|
||||
| Synonyms |
CHEMBL1084400
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C20H21F3N4
|
||||
| Canonical SMILES |
FC(F)(F)c1cccc(c1)c2cc(CCCN3CCCCC3)nc(n2)C#N
|
||||
| InChI |
InChI=1S/C20H21F3N4/c21-20(22,23)16-7-4-6-15(12-16)18-13-17(25-19(14-24)26-18)8-5-11-27-9-2-1-3-10-27/h4,6-7,12-13H,1-3,5,8-11H2
|
||||
| InChIKey |
XGXDWBUGQKHTSH-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | [1587926] | ||
| Cathepsin B | Target Info | [1587926] | |||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentationR-HSA-1442490:Collagen degradation | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.